Anteris Technologies Raises $200 Million with Public Offering and Medtronic Investment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy AVR?
Source: moomoo
Anteris Technologies shares surged 46.09% in pre-market trading, reaching a 20-day high following the announcement of a public offering priced at $5.75 per share for 34.78 million shares, raising approximately $200 million.
The company has entered into a private placement agreement with Medtronic to sell up to $90 million in shares at the public offering price, ensuring Medtronic holds at least 16% of shares post-offering. The proceeds will support the global pivotal PARADIGM trial for the DurAVR® Transcatheter Heart Valve, aimed at treating severe aortic stenosis, and will also fund the expansion of manufacturing capabilities to meet increasing market demand.
This significant capital raise reflects strong market confidence in Anteris's growth strategy and its commitment to advancing cardiac treatment technologies, positioning the company favorably in the competitive healthcare market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVR
Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 19.00 USD with a low forecast of 15.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.220
Low
15.00
Averages
19.00
High
22.00
Current: 5.220
Low
15.00
Averages
19.00
High
22.00
About AVR
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anteris Technologies (AVR) Secures $320M Financing, Price Target Cut to $15
- Financing Impact: Anteris Technologies successfully secured $320 million in financing, including a $90 million strategic investment from Medtronic, which the analyst describes as a 'transformational deal' that will significantly improve the company's capital structure.
- Price Target Adjustment: Lake Street analyst Frank Takkinen lowered Anteris' price target from $20 to $15, primarily due to the dilutive impact of the financing, yet maintains a 'Buy' rating, reflecting confidence in the company's future prospects.
- Strengthened Collaboration: This financing not only alleviates capital overhang but also verifies product viability and solidifies the collaboration with Medtronic, which may become a potential acquirer, enhancing Anteris' market position.
- Market Outlook: The analyst notes that the financing will support Anteris' PARADIGM trial, expected to drive further development in the cardiovascular sector, thereby enhancing its competitiveness in the industry.
See More
Anteris Technologies (AVR) Closes $40 Million Public Offering
- Funding Size: Anteris Technologies successfully closed a $40 million public offering, strengthening its capital base to support future R&D and market expansion.
- Market Reaction: The completion of this offering signifies the company's stable performance in the capital markets, expected to boost investor confidence and provide funding for subsequent projects.
- Strategic Importance: Through this offering, Anteris aims to accelerate its innovation in cardiovascular treatments, further solidifying its market position.
- Future Outlook: The company plans to utilize the raised funds to advance clinical trials and expand its product line, addressing the growing market demand and enhancing competitiveness.
See More
ANTERIS TECHNOLOGIES STOCK RISES 8.7% FOLLOWING $200 MILLION STOCK OFFERING AND MEDTRONIC INVESTMENT ANNOUNCEMENT
- Stock Performance: Anteris Technologies shares increased by 8.7% following the announcement of a $200 million stock offering.
- Investment Focus: The company is focusing on Medtronic investment opportunities as part of its strategic financial moves.
See More
NASDAQ 100 Pre-Market Indicator Drops, TQQQ Volume Surges 188.1%
- TQQQ Trading Surge: ProShares UltraPro QQQ (TQQQ) drops $0.3118 to $50.42 in pre-market, with a volume of 6,158,572 shares traded, reflecting a 188.1% increase from its 52-week low, indicating strong market interest in this ETF.
- NFLX Price Decline: Netflix, Inc. (NFLX) falls $6.745 to $80.52 in pre-market with 5,844,245 shares traded; despite a current mean recommendation in the 'buy range', the price drop may impact investor confidence.
- TSLA Bullish Shares: Direxion Daily TSLA Bull 2X Shares (TSLL) rises $0.01 to $16.42 with 4,565,287 shares traded, representing a 161.05% increase from its 52-week low, reflecting optimism in the Tesla market.
- Positive AVR Recommendation: Anteris Technologies Global Corp. (AVR) increases $0.35 to $6.10 with 4,123,301 shares traded, and the current mean recommendation is in the 'buy range', showing market confidence in its future performance.
See More
Anteris Technologies (AVR) Raises $200 Million with $90 Million Investment from Medtronic (MDT)
- Funding Size: Anteris Technologies announced a $200 million public offering with a 30-day option for underwriters to purchase additional shares, indicating strong market confidence in its future developments.
- Shareholder Structure Change: Medtronic will invest up to $90 million through a wholly-owned subsidiary, expected to hold a 16% to 19.99% stake post-offering, further solidifying its influence in the healthcare technology sector.
- Use of Proceeds: The funds raised will support Anteris' clinical strategy, including patient recruitment and execution of the global PARADIGM pivotal trial, demonstrating the company's ongoing commitment to advancements in heart valve technology.
- Market Reaction: Anteris shares surged approximately 17% in pre-market trading following the offering announcement, reflecting investor optimism about the company's growth potential, particularly in innovative heart disease treatments.
See More
Anteris Technologies Prices Public Offering, Raising Approximately $200 Million
- Stock Surge: Anteris Technologies shares rose over 18% to $6.82 in premarket trading following the pricing of its public offering, indicating strong market confidence in its financing strategy.
- Offering Details: The company priced its public offering at $5.75 per share for 34.78 million shares, raising approximately $200 million, which reflects investor optimism about its future growth prospects.
- Strategic Investment: Anteris plans to sell up to $90 million in shares directly to Medtronic at the same price, enhancing its capital base to support clinical strategies and expand manufacturing capabilities.
- Clinical Trial Progress: The funds will be used to advance the DurAVR Transcatheter Heart Valve's PARADIGM trial, with the first patient implanted in Denmark in Q4 2025, marking a significant step in addressing aortic stenosis treatment.
See More
Anteris Technologies (AVR) Secures $320M Financing, Price Target Cut to $15
- Financing Impact: Anteris Technologies successfully secured $320 million in financing, including a $90 million strategic investment from Medtronic, which the analyst describes as a 'transformational deal' that will significantly improve the company's capital structure.
- Price Target Adjustment: Lake Street analyst Frank Takkinen lowered Anteris' price target from $20 to $15, primarily due to the dilutive impact of the financing, yet maintains a 'Buy' rating, reflecting confidence in the company's future prospects.
- Strengthened Collaboration: This financing not only alleviates capital overhang but also verifies product viability and solidifies the collaboration with Medtronic, which may become a potential acquirer, enhancing Anteris' market position.
- Market Outlook: The analyst notes that the financing will support Anteris' PARADIGM trial, expected to drive further development in the cardiovascular sector, thereby enhancing its competitiveness in the industry.
See More
Anteris Technologies (AVR) Closes $40 Million Public Offering
- Funding Size: Anteris Technologies successfully closed a $40 million public offering, strengthening its capital base to support future R&D and market expansion.
- Market Reaction: The completion of this offering signifies the company's stable performance in the capital markets, expected to boost investor confidence and provide funding for subsequent projects.
- Strategic Importance: Through this offering, Anteris aims to accelerate its innovation in cardiovascular treatments, further solidifying its market position.
- Future Outlook: The company plans to utilize the raised funds to advance clinical trials and expand its product line, addressing the growing market demand and enhancing competitiveness.
See More
ANTERIS TECHNOLOGIES STOCK RISES 8.7% FOLLOWING $200 MILLION STOCK OFFERING AND MEDTRONIC INVESTMENT ANNOUNCEMENT
- Stock Performance: Anteris Technologies shares increased by 8.7% following the announcement of a $200 million stock offering.
- Investment Focus: The company is focusing on Medtronic investment opportunities as part of its strategic financial moves.
See More
NASDAQ 100 Pre-Market Indicator Drops, TQQQ Volume Surges 188.1%
- TQQQ Trading Surge: ProShares UltraPro QQQ (TQQQ) drops $0.3118 to $50.42 in pre-market, with a volume of 6,158,572 shares traded, reflecting a 188.1% increase from its 52-week low, indicating strong market interest in this ETF.
- NFLX Price Decline: Netflix, Inc. (NFLX) falls $6.745 to $80.52 in pre-market with 5,844,245 shares traded; despite a current mean recommendation in the 'buy range', the price drop may impact investor confidence.
- TSLA Bullish Shares: Direxion Daily TSLA Bull 2X Shares (TSLL) rises $0.01 to $16.42 with 4,565,287 shares traded, representing a 161.05% increase from its 52-week low, reflecting optimism in the Tesla market.
- Positive AVR Recommendation: Anteris Technologies Global Corp. (AVR) increases $0.35 to $6.10 with 4,123,301 shares traded, and the current mean recommendation is in the 'buy range', showing market confidence in its future performance.
See More
Anteris Technologies (AVR) Raises $200 Million with $90 Million Investment from Medtronic (MDT)
- Funding Size: Anteris Technologies announced a $200 million public offering with a 30-day option for underwriters to purchase additional shares, indicating strong market confidence in its future developments.
- Shareholder Structure Change: Medtronic will invest up to $90 million through a wholly-owned subsidiary, expected to hold a 16% to 19.99% stake post-offering, further solidifying its influence in the healthcare technology sector.
- Use of Proceeds: The funds raised will support Anteris' clinical strategy, including patient recruitment and execution of the global PARADIGM pivotal trial, demonstrating the company's ongoing commitment to advancements in heart valve technology.
- Market Reaction: Anteris shares surged approximately 17% in pre-market trading following the offering announcement, reflecting investor optimism about the company's growth potential, particularly in innovative heart disease treatments.
See More
Anteris Technologies Prices Public Offering, Raising Approximately $200 Million
- Stock Surge: Anteris Technologies shares rose over 18% to $6.82 in premarket trading following the pricing of its public offering, indicating strong market confidence in its financing strategy.
- Offering Details: The company priced its public offering at $5.75 per share for 34.78 million shares, raising approximately $200 million, which reflects investor optimism about its future growth prospects.
- Strategic Investment: Anteris plans to sell up to $90 million in shares directly to Medtronic at the same price, enhancing its capital base to support clinical strategies and expand manufacturing capabilities.
- Clinical Trial Progress: The funds will be used to advance the DurAVR Transcatheter Heart Valve's PARADIGM trial, with the first patient implanted in Denmark in Q4 2025, marking a significant step in addressing aortic stenosis treatment.
See More
